$PIRS
PIERIS PHARMACEUTICALS, INC.

2016 Q4 Form 10-Q Financial Statement

#000119312516765868 Filed on November 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $2.730M $785.0K $414.6K
YoY Change 27.57% 89.34% 2114.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.210M $2.340M $2.240M
YoY Change 25.57% 4.46% 140.86%
% of Gross Profit
Research & Development $6.920M $4.622M $2.052M
YoY Change 135.37% 125.28% 121.42%
% of Gross Profit
Depreciation & Amortization $180.0K $100.0K $80.00K
YoY Change 125.0% 25.0% -11.11%
% of Gross Profit
Operating Expenses $9.130M $6.963M $4.294M
YoY Change 94.26% 62.14% 130.91%
Operating Profit -$6.178M -$3.880M
YoY Change 59.23% 110.74%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $10.00K -$18.24K -$1.929K
YoY Change 0.0% 845.72% -1403.38%
Pretax Income -$6.400M -$6.196M -$3.882M
YoY Change 133.58% 59.62% 91.96%
Income Tax $160.0K $0.00 $40.44K
% Of Pretax Income
Net Earnings -$6.560M -$6.196M -$3.922M
YoY Change 126.21% 57.98% 93.96%
Net Earnings / Revenue -240.29% -789.32% -946.01%
Basic Earnings Per Share
Diluted Earnings Per Share -$152.3K -$144.0K -$100.8K
COMMON SHARES
Basic Shares Outstanding 43.06M shares 43.06M shares 39.73M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.40M $36.60M $32.30M
YoY Change 0.34% 13.31%
Cash & Equivalents $29.36M $36.56M $32.25M
Short-Term Investments
Other Short-Term Assets $3.300M $4.600M $1.285M
YoY Change 43.48% 257.97%
Inventory
Prepaid Expenses $589.9K
Receivables $57.00K $17.36K
Other Receivables $0.00 $0.00
Total Short-Term Assets $32.67M $41.14M $34.15M
YoY Change 3.2% 20.46%
LONG-TERM ASSETS
Property, Plant & Equipment $2.264M $2.448M $1.928M
YoY Change 4.68% 26.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $126.0K $127.6K $97.11K
YoY Change -0.62% 31.42%
Total Long-Term Assets $2.390M $2.575M $2.050M
YoY Change 4.39% 25.64%
TOTAL ASSETS
Total Short-Term Assets $32.67M $41.14M $34.15M
Total Long-Term Assets $2.390M $2.575M $2.050M
Total Assets $35.06M $43.71M $36.20M
YoY Change 3.28% 20.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.386M $4.500M $1.100M
YoY Change 125.41% 309.09%
Accrued Expenses $3.719M $2.898M $1.034M
YoY Change 113.81% 180.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $8.380M $9.952M $2.242M
YoY Change 199.51% 343.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $47.00K $44.57K $300.0K
YoY Change 97.05% -85.15%
Total Long-Term Liabilities $47.00K $44.57K $300.0K
YoY Change 97.05% -85.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.380M $9.952M $2.242M
Total Long-Term Liabilities $47.00K $44.57K $300.0K
Total Liabilities $9.836M $12.23M $2.550M
YoY Change 248.58% 379.67%
SHAREHOLDERS EQUITY
Retained Earnings -$102.7M -$96.11M -$76.96M
YoY Change 28.55% 24.87%
Common Stock $129.4M $128.9M $39.76K
YoY Change 15.26% 324130.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.23M $31.48M $33.65M
YoY Change
Total Liabilities & Shareholders Equity $35.06M $43.71M $36.20M
YoY Change 3.28% 20.75%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$6.560M -$6.196M -$3.922M
YoY Change 126.21% 57.98% 93.96%
Depreciation, Depletion And Amortization $180.0K $100.0K $80.00K
YoY Change 125.0% 25.0% -11.11%
Cash From Operating Activities -$6.730M -$3.580M -$3.530M
YoY Change 169.2% 1.42% 110.12%
INVESTING ACTIVITIES
Capital Expenditures -$260.0K -$200.0K -$200.0K
YoY Change -25.71% 0.0% 1900.0%
Acquisitions
YoY Change
Other Investing Activities $20.00K
YoY Change
Cash From Investing Activities -$240.0K -$200.0K -$200.0K
YoY Change -31.43% 0.0% 1900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -60.00K 25.78M
YoY Change -100.0% -100.23% 1946.03%
NET CHANGE
Cash From Operating Activities -6.730M -3.580M -3.530M
Cash From Investing Activities -240.0K -200.0K -200.0K
Cash From Financing Activities 0.000 -60.00K 25.78M
Net Change In Cash -6.970M -3.840M 22.05M
YoY Change 145.42% -117.41% -5227.91%
FREE CASH FLOW
Cash From Operating Activities -$6.730M -$3.580M -$3.530M
Capital Expenditures -$260.0K -$200.0K -$200.0K
Free Cash Flow -$6.470M -$3.380M -$3.330M
YoY Change 200.93% 1.5% 99.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43058827 shares
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32254879
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
983951
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11116544
CY2016Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4523798
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1325104
CY2016Q3 us-gaap Cash
Cash
36557701
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43058827 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43058827 shares
CY2016Q3 us-gaap Assets
Assets
43712719
CY2016Q3 us-gaap Assets Current
AssetsCurrent
41137360
CY2016Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
128870853
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36557701
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
43059
CY2016Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
0
CY2016Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2233834
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2529661
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
360200
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2898388
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
4963 shares
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4963 shares
CY2016Q3 us-gaap Liabilities
Liabilities
12230246
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43712719
CY2016Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44565
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9951847
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
140799
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
127626
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2447733
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
31482473
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96106340
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4579659
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4963 shares
CY2016Q3 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
394414
CY2016Q3 pirs Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2898388
CY2016Q3 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
1019024
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18474211
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
704597
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Cash
Cash
29349124
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39833023 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39833023 shares
CY2015Q4 us-gaap Assets
Assets
33950061
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-269265
CY2015Q4 us-gaap Assets Current
AssetsCurrent
31660509
CY2015Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
112226723
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29349124
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
39833
CY2015Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
0
CY2015Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1058536
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
194790
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1272574
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1739380
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
4963 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Liabilities
Liabilities
2821768
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33950061
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23852
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2797916
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
194694
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
126781
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2162771
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
31128293
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79865689
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2311385
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
179223
CY2015Q4 pirs Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1739380
CY2015Q4 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
466076
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
13780668
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
823164
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6606209
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-342653
us-gaap Depreciation
Depreciation
234066
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11464167
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4223
us-gaap Revenues
Revenues
792474
us-gaap Interest Paid
InterestPaid
4181
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3325
us-gaap Income Taxes Paid
IncomeTaxesPaid
40441
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-49427
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
190549
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-307182
us-gaap Operating Expenses
OperatingExpenses
11908120
us-gaap Net Income Loss
NetIncomeLoss
-11156985
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0189 pure
us-gaap Repayments Of Debt
RepaymentsOfDebt
1157940
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7507 pure
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17328
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
10109
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
768982
us-gaap Operating Income Loss
OperatingIncomeLoss
-11115646
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
24606020
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-307182
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40441
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10213434
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
269265
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.94
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5301911
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0149 pure
us-gaap Share Based Compensation
ShareBasedCompensation
823164
us-gaap Restricted Stock Expense
RestrictedStockExpense
446400
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7265 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32584354 shares
pirs Proceeds From Issuance Of Common And Preferred Stock
ProceedsFromIssuanceOfCommonAndPreferredStock
25763960
pirs Non Cash Consulting Shares
NonCashConsultingShares
75000
dei Entity Registrant Name
EntityRegistrantName
PIERIS PHARMACEUTICALS, INC.
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001583648
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7208577
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1426341
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
0
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6677110
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-30993
us-gaap Depreciation
Depreciation
175387
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16293041
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Revenues
Revenues
3104513
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
113575
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3304055
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1139045
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-52530
us-gaap Operating Expenses
OperatingExpenses
19458599
us-gaap Net Income Loss
NetIncomeLoss
-16240511
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16240511
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-322706
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2161864
us-gaap Operating Income Loss
OperatingIncomeLoss
-16354086
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15221021
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-52530
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4698803
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12781489
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7658745
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
322706
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0161 pure
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses in the financial statements and disclosures in the accompanying notes. Significant estimates are used for, but are not limited to, revenue recognition, deferred tax assets, liabilities and valuation allowances, fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management&#x2019;s estimates, judgments and assumptions.</p> </div>
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7600 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.01
dei Trading Symbol
TradingSymbol
PIRS
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0113 pure
us-gaap Share Based Compensation
ShareBasedCompensation
1426341
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7490 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41259749 shares
pirs Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
83435
pirs Proceeds From Issuance Of Common And Preferred Stock
ProceedsFromIssuanceOfCommonAndPreferredStock
15221021
CY2016Q2 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
1 shares
CY2016Q2 pirs Warrant Exercisable Period
WarrantExercisablePeriod
P5Y
CY2015Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
25800000
CY2015Q3 pirs Gross Proceeds From Issuance Initial Public Offering
GrossProceedsFromIssuanceInitialPublicOffering
28300000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
337789
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2242804
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3728837
CY2015Q3 us-gaap Revenues
Revenues
414610
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1929
CY2015Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
193415
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
4294492
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-3922252
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3881811
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3879882
CY2015Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
193415
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40441
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0189 pure
CY2015Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7343 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.95
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2051688
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0169 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7265 pure
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38890546 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
446113
CY2016Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
0
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2341010
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6195533
CY2016Q3 us-gaap Revenues
Revenues
785007
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18243
CY2016Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
670
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
6962967
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-6196203
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6196203
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6177960
CY2016Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
670
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0135 pure
CY2016Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7512 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.05
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4621957
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0125 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7490 pure
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43063790 shares

Files In Submission

Name View Source Status
0001193125-16-765868-index-headers.html Edgar Link pending
0001193125-16-765868-index.html Edgar Link pending
0001193125-16-765868.txt Edgar Link pending
0001193125-16-765868-xbrl.zip Edgar Link pending
d268927d10q.htm Edgar Link pending
d268927dex311.htm Edgar Link pending
d268927dex312.htm Edgar Link pending
d268927dex321.htm Edgar Link pending
d268927dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pirs-20160930.xml Edgar Link completed
pirs-20160930.xsd Edgar Link pending
pirs-20160930_cal.xml Edgar Link unprocessable
pirs-20160930_def.xml Edgar Link unprocessable
pirs-20160930_lab.xml Edgar Link unprocessable
pirs-20160930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending